Product Description:
LUOFUCON®Silver Alginate Dressing is a non-woven pad composed of calcium alginate and silver particles. The silver content is 50µg/100 cm2. The silver particles are in the form of encapsulated metallic silver, which is very stable and won't be oxidized even on exposure to light.
LUOFUCON® Silver Alginate Dressing is proved to have broad spectrum antibacterial effect , based on in vitro laboratory testing.
1. Silver Release
Figure1 shows that LUOFUCON® Silver Alginate Dressing leaches about 57% of the total silver during the first 24 hours, and 30%, 24% of its total silver during 24-48, 48-72 hours, respectively.
The release profiles indicates that the release of silver from the dressing is well controlled.
Note:
Two pieces of the dressing in the size of 10 x 10 cm were used in this test. The test was performed by China National Analytical Center at Guangzhou.
LUOFUCON® Silver Alginate Dressing leaches about 57% of the total silver during the first 24 hours, and 30%, 24% of its total silver during 24-48, 48-72 hours, respectively.
The release profiles indicates that the release of silver from the dressing is well controlled.
Antibacterial Effectiveness Test
AATCC 100-2004 only specifies the use of one Gram-positive and one Gram-negative bacteria. However, we tested six clinical-relevant bacteria ( 3 Gram-positive and 3 Gram-negative bacteria) for the evaluation of antibacterial effectiveness.
Test Organism | Test Method |
Enterococcus faecalis | ATCC 29219 | Dressing specimens and controls were tested under simulated use conditions for seven days. During this time, test articles were kept moistened daily with phosphate buffered water containing 10% Fetal Bovine Serum to simulate daily use. The antibacterial activity testing was performed with an inoculum challenge of more than 106 CFU total. |
Escherichia coli | ATCC 8739 |
Klebsiella pneumoniae | ATCC 4352 |
Pseudomonas aeruginosa | ATCC 9027 |
Staphylococcus aureus | ATCC 6538 |
Streptococcus pyogenes | ATCC 19615 |
Table 1: 1 Day Antibacterial Effectiveness
| 1 Day |
| Replicate 1 | Replicate 2 | Replicate 3 |
Staphylococcus aureus | >4.0 | >4.1 | >4.1 |
Streptococcus pyogenes | >4.4 | >4.4 | >4.3 |
Enterococcus faecalis | >4.3 | >4.2 | >4.3 |
Escherichia coli | >4.2 | >4.2 | >4.13 |
Klebsiella pneumoniae | >4.1 | >4.0 | >4.1 |
Pseudomonas aeruginosa | >4.1 | >4.1 | >4.1 |
Table 2: 7 Days Antibacterial Effectiveness
| 7 Day |
| Replicate 1 | Replicate 2 | Replicate 3 |
Staphylococcus aureus | >4.0 | >4.0 | >4.0 |
Streptococcus pyogenes | >4.1 | >4.1 | >4.1 |
Enterococcus faecalis | 2.1 | 1.6 | 2.6 |
Escherichia coli | >4.3 | >4.3 | >4.3 |
Klebsiella pneumoniae | >4.2 | >4.2 | >4.2 |
Pseudomonas aeruginosa | >4.0 | >4.0 | >4.0 |
2.3 Additional Study
Besides the six clinical-relevant bacteria above, we made an additional study for one drug-resistant bacteria(MRSA) and one fungus(Candida albicans).